imageSlide

Minimize our environmental impact

60px
medium
false
Man running outside
white
OUR IMPACT

Our purpose of making life better includes protecting and preserving the world we live in.

60px

Making medicines requires the use of valuable resources including energy, water and raw materials. We’re committed to reducing our environmental footprint. We have set sustainability goals to reduce our emissions and waste and to continue using water responsibly and efficiently.

See our latest environmental reporting.

20px
spacer
large
spacer
large
spacer
large
spacer
large
left

2030 
Environmental
goals

100px
3-col
snowflake icon

Climate

48px

Carbon neutral in our own operations

100% renewable electricity

Enhance full value-chain emissions reporting

20px
Trash icon

Waste

48px

Zero waste to landfills from routine operations

100% of plastic waste for beneficial use, with at least 90% recycled or reused

Integrate sustainability into product and packaging design

20px

Water

48px

No adverse impact to water-stressed areas

No adverse impact from pharmaceuticals in the environment

20px
none
Climate
24px
standardTitle
2Column
contentTypeNone
secContentTypeIcon

Lilly acknowledges that climate change is negatively impacting human and environmental health. Action against climate change is required to achieve the goals of the Paris Climate Agreement and to avoid the most detrimental effects of climate change by limiting the global temperature rise to 1.5 °C. As a global company committed to making life better for people, Lilly recognizes our responsibility to reduce our greenhouse gas emissions to help fight climate change. Lilly’s 2030 goals are to source 100% of our purchased electricity from renewable sources and to achieve carbon neutrality in our operations (scope 1 and scope 2). Learn more about our approach to climate.

2030 climate goals:

  • Sourcing 100% of our purchased electricity from renewable sources
  • Become carbon neutral in our own operations (scope 1 and 2 emissions)
  • Enhance tracking and reporting of emissions from our full value chain
16px
Waste
24px
standardTitle
2Column
contentTypeNone
secContentTypeIcon

Lilly is committed to minimizing waste to conserve energy, resources and landfill space. We understand that the most effective way to reduce waste is to not create it in the first place, which is why we explore ways to reduce, reuse or recycle materials to make new products. We recover energy from waste when possible and treat waste to reduce toxicity and volume. We only send waste to the landfill as a last resort or when legally required. Our goals are to achieve zero waste to landfills, and to ensure all plastic waste is repurposed for beneficial use. Learn more about our approach to waste.

2030 waste goals:

  • Ensuring zero waste to landfill from routine operations
  • Repurposing 100% of plastic waste for beneficial use, with at least 90% recycled or reused
  • Integrate sustainability-focused design principles into product and packaging design processes
16px
Water
24px
standardTitle
2Column
contentTypeNone
secContentTypeIcon

Water is essential to our operations and the facilities where we discover and manufacture our medicines, and we’re committed to using this critical resource efficiently. We aim to manage water more sustainably by reducing our water footprint and avoiding potential risks related to pharmaceuticals in the environment (PiE).

We assess our water risks, and while we generally operate in locations where the risk of water scarcity and poor quality are low, we continue to focus on conserving and reducing water use and improving the quality of the water we discharge from our facilities. We work with our sites around the world to identify water-saving opportunities and wastewater treatment technologies to support our environmental goals. Learn more about our approach to water use.

2030 water goals:

  • Establish and implement water management plans for Lilly sites in water-stressed areas and conform to plans
  • Ensuring 100% of Lilly sites meet predicted no-effect concentrations (PNEC) for Pharmaceuticals in the Environment
  • Ensuring appropriate controls are in place by Lilly contract manufacturers to prevent discharge of pharmaceuticals in wastewater above applicable PNEC values
16px
Product stewardship
24px
standardTitle
2Column
contentTypeNone
secContentTypeIcon
Each stage of the pharmaceutical product life cycle includes distinct environmental considerations and opportunities. We take a broad approach to understanding and managing potential environmental issues across our value chain, from development of new medicines to product end-of-life and disposal considerations. As the phase of research and development significantly influences the environmental footprint of pharmaceutical manufacturing, we integrate sustainability-focused design principles – such as green chemistry and end-product engineering – early in product development. These design principles help identify and reduce health, safety and environmental impacts from production processes when possible. As our product portfolio evolves and grows, we continue to search for new and better ways to reduce our environmental footprint across the life cycle of our products. Learn more about our approach to product stewardship.
16px
spacer
large
spacer
medium

State-specific requirements

60px
Lilly supports the safe collection and proper disposal of syringes, needles and other sharps generated in home settings. For this reason and to comply with laws addressing sharps disposal, our Safe Sharps Disposal Plan is made available to the public on this website, along with more important compliance information.
20px
one
View our sustainability report
link
https://sustainability.lilly.com/
newTab
select
spacer
large
spacer
large
spacer
large
spacer
large
spacer
large
spacer
large
center

We know that how we operate our business today can have a long-lasting impact on people and the planet. That's why Lilly takes a broad approach to understanding and managing our environmental impacts across the product life cycle.

48px
David Sternasty
Vice President, Corporate Engineering and Global Health, Safety and Environment
spacer
large
spacer
large
Dave Ricks and Micheál Martin at the Lilly Solar Farm in Kinsale, Ireland

Expanding our use of solar energy at our global facilities

48px
More on the renewable efforts
link
/news/stories/expanding-our-use-of-solar-energy-at-our-global-facilities
spacer
large
spacer
large
spacer
large
spacer
large
left

Lilly cautionary statement regarding forward-looking statements

24px
This website contains forward-looking statements that are based on management’s assumptions and expectations at the time the statements were posted, including statements regarding our sustainability targets, goals, commitments and programs and other business plans, initiatives, aspirations and objectives. The words “estimate”, “project”, “intend”, “expect”, “believe”, “target”, “anticipate” and similar expressions are intended to identify forward-looking statements. All such statements are intended to enjoy the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially due to various factors. The company’s sustainability targets, goals, and commitments outlined in this website or elsewhere, as well as its operations, results, business, goals, and strategy may be affected by factors including, but not limited to, the impact of the evolving COVID-19 pandemic (or any other public health threat) and the global response thereto; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; competitive developments affecting current products and the company’s pipeline; regulatory actions regarding currently marketed products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured; the impact and outcome of business development transactions and related integration costs; the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war or other costs or uncertainties related to doing business in foreign jurisdictions; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions or shortages, including as a result of demand, labor shortages, third-party performance or regulatory actions relating to our facilities; and changes or developments in laws and regulations, including health care reform.

For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company expressly disclaims any obligation to update forward-looking statements except as required by applicable law.

Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.
20px